Contact Us
Drug Search Results
More Filters [+]

Clodronic acid

Alternative Names: clodronic acid, clodronate, bonefos
Latest Update: 2025-01-03
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Osteoclast Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Dominican Republic | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | Indonesia | Ireland | Israel | Italy | Jordan | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Slovenia | Spain | Sweden | Taiwan | Thailand | Tunisia | Turkey | United Kingdom | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Clodronic acid

Countries in Clinic: Italy

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Osteoarthritis, Knee

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
SPA-S-899-01-21

P3

Unknown Status

Osteoarthritis, Knee

2025-10-01

SPA-S-899-01-21

P3

Recruiting

Osteoarthritis, Knee

2025-07-01

SPA-S-899-01-21

P3

Active, not recruiting

Osteoarthritis, Knee

2025-05-15

Recent News Events

Date

Type

Title

09/06/2023

News Article

 With 11.71% CAGR, Global Hypercalcemia Treatment Market Size Likely to Hit $39.29 Billion by 2031, Share, Growth, Technology Trends & Market Research

07/14/2022

News Article

 Study shows that selection of breast cancer patients for adjuvant bisphosphonate therapy based on Inbiomotion's MAFTEST® reduces the risk of death in comparison with current clinical guidance

09/30/2021

News Article

 Inbiomotion's MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions